eureKASYNBIO
ActiveSummary
The computed 12-month bankruptcy probability of eureKASYNBIO is 3.0% (moderate). For eureKASYNBIO, at least two filing cycles of the annual accounts are missing. The 2023 annual accounts show equity of €2.0m and a net result of -€4,849. The company has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals.
Group and network
Holdings and subsidiaries
2 holdingsHoldings 2
Source for every holding own accounts 2023
- Dirac BiosciencessubsidiaryEquity -€3,188Result -€3,188100%
- EonbiosubsidiaryEquity -€4,028Result -€4,028100%
According to the 2023 annual accounts of eureKASYNBIO and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
1 current directorThe network starts from this company’s directors. Other companies they run appear here as nodes.